This site is intended for healthcare professionals

Two pivotal Phase III studies evaluating RM 493 in POMC and LEPR published in The Lancet Diabetes & Endocrinology.- Rhythm Pharma

Read time: 1 mins
Last updated:3rd Nov 2020
Published:1st Nov 2020
Condition: Pro-opiomelanocortin (POMC) Deficiency Obesity
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest